Inactive Instrument

OKYO Pharma Limited London S.E.

OKYO

GG00BMFG5F62

West African Minerals Corporation has Changed its Name to OKYO Pharma Corporation

January 10, 2018 at 12:00 am EST

On January 10, 2018, West African Minerals Corporation changed its name to OKYO Pharma Corporation.

Latest news about OKYO Pharma Limited

OKYO Pharma Limited Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease	Jul. 10	CI
H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	Mar. 22	MT
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	Mar. 22	CI
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	Mar. 20	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09	MT
Sector Update: Health Care	Feb. 09	MT
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	Feb. 09	MT
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	Feb. 09	CI
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	Jan. 31	CI
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	Jan. 08	CI
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	Dec. 04	CI
HC Wainwright Initiates Coverage on OKYO Pharma with Buy Rating, $4 Price Target	Nov. 02	MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday	23-10-09	MT
OKYO Pharma Submits Investigational New Drug Application for OK-101 in Neuropathic Corneal Pain	23-10-09	MT
Okyo Pharma Limited Announces Filing of an Investigational New Drug Application for Ok-101 to Treat Neuropathic Corneal Pain	23-10-09	CI
OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease	23-10-05	CI
Traders Digest Fresh Batch of Data, Stifling US Equity Futures Pre-Bell	23-09-15	MT
Top Premarket Decliners	23-09-15	MT
Sector Update: Health Care Stocks Rising Late Afternoon	23-09-14	MT
Sector Update: Health Care Stocks Rising in Afternoon Trading	23-09-14	MT
OKYO Pharma Prices $4 Million Share Offering	23-09-14	MT
Top Premarket Decliners	23-09-14	MT
OKYO Pharma Plans Share Offering; Stock Down After-Hours	23-09-13	MT
Top Premarket Decliners	23-09-13	MT
Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease	23-09-08	CI

OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	42.34B
BIOGEN INC.	-11.76%	32.76B
UCB	+79.34%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-12.20%	16.31B
INCYTE CORPORATION	+4.00%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.23B
ALTEOGEN INC.	+178.17%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	+1.80%	8.97B

Biopharmaceuticals